For breast cancer, Ki-67 analysis is relevant for estrogen receptor positive (ER+) early stage breast cancer [3–5] which presents as a spectrum of tumors with clinically indolent (Luminal A) or more aggressive features (Luminal B) [6]. Here, MKI67 is linked to breast carcinoma.